Skip to main content
SpringerLink
Log in

Calcium channel antagonists in the modern era of coronary thrombolysis: Benefit or detriment?

  • Editorial: Focus on Calcium Antagonists
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Calcium channel antagonists are among the world's most widely prescribed class of drugs and are used most often in patients with hypertension and coronary artery disease. However, in the recent past serious questions have been raised concerning their potentially detrimental effects. One area of considerable clinical importance that deserves close inspection is the role of calcium channel antagonists following coronary reperfusion. Specifically, is there benefit or detriment?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Opie LH, Frishman WH, Thadani U. Calcium channel antagonists. In: Opie LH, ed. Drugs for the Heart, 4th ed. Philadelphia: WB Saunders, 1994.

    Google Scholar 

  2. Frishman WH. Current status of calcium channel blockers. Curr Probl Cardiol 1994;19:637–688.

    Google Scholar 

  3. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1983;307:1618–1627.

    Google Scholar 

  4. Frishman WH, Stroh JA, Greenberg SM, et al. Calcium channel blockers in systemic hypertension. Med Clin North Am 1988;72:449–499.

    Google Scholar 

  5. Zing W, Ferguson RK, Vlasses PH. Calcium antagonists in elderly and black hypertensive patients: Therapeutic controversies. Arch Intern Med 1991;151:2154–2162.

    Google Scholar 

  6. Skolnick AE, Frishman WH. Calcium channel blockers in myocardial infarction. Arch Intern Med 1989;149:1669–1677.

    Google Scholar 

  7. Kaitenback M, Hopf R, Kober G, et al. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J 1979;42:35–42.

    Google Scholar 

  8. Frishman WH, Skolnick AE. Effects of calcium blockade on hypertension-induced left ventricular hypertrophy. Circulation 1989;80(Suppl IV):151–161.

    Google Scholar 

  9. Philipson KD, Nashimoto AY. Na+-Ca2+ exchange in inside-out cardiac sarcolemmal vesicles. J Biol Chem 1982; 257:5111–5117.

    Google Scholar 

  10. Kusvoka H, Porterfield JK, Weisman HF, Weisfeldt ML, Marban E. Pathophysiology and pathogenesis of stunned myocardium: Depressed Ca2+ activation of contraction as a consequence of reperfusion-induced cellular calcium overload in ferret hearts. J Clin Invest 1987;79:950–961.

    Google Scholar 

  11. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized double-blind, placebo-controlled comparison. Circulation 1984;69:740–747.

    Google Scholar 

  12. Sirnes PA, Overskeid K, Pedersen TR, et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: The Norwegian Nifedipine Multicenter Trial. Circulation 1984;70:638–644.

    Google Scholar 

  13. Loogna E, Sylven C, Groth T, Mogensen L. Complexity of enzyme release during acute myocardial infarction in a controlled study with early nifedipine treatment. Eur Heart J 198;6:114–119.

  14. Eisenberg PR, Lee RG, Biello DR, Geltman EM, Jaffe AS. Chest pain after nontransmural infarction: The absence of remediable coronary vasospasm. Am Heart J 1985;110: 515–521.

    Google Scholar 

  15. Wilcox RG, Hampton JR, Banks BC, et al. Trial of early nifedipine in acute myocardial infarction. The Trent Study. Br Med J 1986;293:1204–1208.

    Google Scholar 

  16. Neufeld NH. Calcium antagonists in secondary prevention after acute myocardial infarction: The Secondary Prevention Reinfarction Nifedipine Trial (SPRINT). Eur Heart J 1986;7(Suppl B):51–52.

    Google Scholar 

  17. The Israeli SPRINT Study Group: Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354–364.

    Google Scholar 

  18. Report of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group: Early treatment of unstable angina in the coronary care unit: A randomized, double-blind placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both Br Heart J 1986;56:400–413.

  19. Erbel R, Pop T, Meinertz T. Combination of calcium channel blocker and thrombolytic therapy in acute myocardial infarction. Am Heart J 1988;115:529–538.

    Google Scholar 

  20. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326–1331.

    Google Scholar 

  21. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Hematol Oncol Clin North Am 1990; 4:1–26.

    Google Scholar 

  22. Murer EH. The role of platelet calcium. Semin Hematol 1985;22:313–323.

    Google Scholar 

  23. Avdonin PV, Menshikov MY, Svitina-Ulitina IV, Tkachuk VA. Blocking of the receptor-stimulated calcium entry into human platelets by verapamil and nicardipine. Thromb Res 1988;52:587–597.

    Google Scholar 

  24. Moore JB, Fuller BL, Falotico R, Tollman EL. Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers. Thromb Res 1985;40: 401–411.

    Google Scholar 

  25. Epstein PM, Fiss K, Hachisu R, Andrenyak DM. Interaction of calcium antagonists with cyclic AMP phosphodiesterases and calmodulin. Biochem Biophys Res Commun 1982; 105:1142–1149.

    Google Scholar 

  26. Davi G, Noso S, Fiore M. Effects of nifedipine on thromboxane synthesis in vitro and in vivo. Thromb Res 1982;28: 837–842.

    Google Scholar 

  27. Lee SL, Long K, Veda S, Fanburg BL. Verapamil inhibits serotonin uptake of endothelial cells in culture by a mechanism unrelated to Ca2+ channel blockade. J Cell Physiol 1987:132:178–182.

    Google Scholar 

  28. Affulter H, Burkard WP, Pletscher A. Verapamil an antagonist at 5-hydroxytryptamine receptors of human platelets. Eur J Pharmacol 1985;108:157–162.

    Google Scholar 

  29. Baudouin-Legros M, Dard B, Guichency P, Meyer P. Double action of nicardipine on serotonin release from rat platelets. J Cardiovasc Pharmacol 1987;10:287–292.

    Google Scholar 

  30. Rybak MEM Renzulli LA. Effect of calcium channel blockers on platelet GPIIb-IIIa as a calcium channel in liposomes: Comparison with effects on the intact platelet. Thromb Res 1991;65:131–136.

    Google Scholar 

  31. Takahara K, Kuroiwa A, Matsushima T. Effects of nifedipine on platelet function. Am Heart J 1985;109:4–7.

    Google Scholar 

  32. Greer IA, Walker JJ, McLaren M. Inhibition of whole blood platelet aggregation by nicardipine, and synergism with prostacyclin in vitro. Thromb Res 1986;41:509–518.

    Google Scholar 

  33. Jones CR, Pasanisi G, Elliott HL, Reid JL. Effect of verapamil and nisoldipine on human platelets: In vivo and in vitro studies. Br J Clin Pharmacol 1985;20:191–196.

    Google Scholar 

  34. Schacter M. Do calcium antagonists affect platelets? Eur Heart J 1987;8(Suppl K):75–82.

    Google Scholar 

  35. Pumphrey CW, Fuster V, Dewanjee MK, Chesebro JH, Vlietstra RE, Kaye MP. Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs. Am J Cardiol 1983;51:591–595.

    Google Scholar 

  36. Becker RC, Caputo R, Ball S, Corrao JM, Baker S, Gore JM. Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration. Am Heart J 1993;126:11–14.

    Google Scholar 

  37. Wagenknecht LE, Furberg CD, Hammon JW, et al. Surgical bleeding: Unexpected effect of a calcium antagonist. Br Med J 1995;310:776.

    Google Scholar 

  38. Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, Pilot and Clinical Trial. Circulation 1991;83:448–459.

    Google Scholar 

  39. Maggioni AP, Franzosi MG, Santoro E, White H, Van deWerf F, Tognoni G, the Gruppo Italiano per lo Studio della Sopravvivenza nell 'Infarto miocardico II (GISSI-2), and The International Study Group. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med 1992;327: 1–6.

    Google Scholar 

  40. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620–625.

    Google Scholar 

  41. Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990;82:897–902.

    Google Scholar 

  42. Grignani G, Soffiantino F, Zucchella M, et al. Platelet activation by emotional stress in patients with coronary artery disease. Circulation 1991;83(Suppl II):II-128-II-136.

    Google Scholar 

  43. Hjemdahl P, Chronos NA, Wilson DJ, Bouloux P, Goodall AH. Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler Thromb 1994;14:77–84.

    Google Scholar 

  44. Prisco D, Paniccia R, Guarnaccia V, et al. Thrombin generation after physical exercise. Thromb Res 1993;69:159–164.

    Google Scholar 

  45. Andreotti F, Davies GJ, Hackett DR, et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988;62:635–637.

    Google Scholar 

  46. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79:101–106.

    Google Scholar 

  47. Bridges AB, McLaren M, Scott NA, Pringle TH, McNeill GP, Belch JJ. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. Br Heart J 1993;69:121–124.

    Google Scholar 

  48. Alderman MH, Madhaven S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098–1104.

    Google Scholar 

  49. Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential infarction between the renin angiotensin system and fibrinolytic function. Circulation 1993;87:1969–1973.

    Google Scholar 

  50. Tusu F, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173–1178.

    Google Scholar 

  51. Rogers WJ, Bowlby LJ, Chandra NC, et al, for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993): Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103–2114.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Thrombosis Research Center, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA

    John A. Foley & Richard C. Becker

Authors
  1. John A. Foley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard C. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Foley, J.A., Becker, R.C. Calcium channel antagonists in the modern era of coronary thrombolysis: Benefit or detriment?. Cardiovasc Drug Ther 10, 403–407 (1996). https://doi.org/10.1007/BF00051103

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00051103

Key Words

Search

Navigation